ziprasidone has been researched along with n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartenstein, P; Boy, C; Bröcheler, A; Buchholz, HG; Cumming, P; Fellows, C; Gründer, G; Hiemke, C; Janouschek, H; Landvogt, C; Rösch, F; Schäfer, W; Spreckelmeyer, K; Vernaleken, I; Veselinovic, T; Wong, DF | 1 |
1 trial(s) available for ziprasidone and n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide
| Article | Year |
|---|---|
Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzamides; Binding, Competitive; Carbon Radioisotopes; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Fluorine Radioisotopes; Humans; Male; Piperazines; Positron-Emission Tomography; Pyrrolidines; Raclopride; Radiopharmaceuticals; Receptors, Dopamine D2; Receptors, Dopamine D3; Schizophrenia; Thiazoles; Time Factors; Young Adult | 2008 |